Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized peptide vaccination in ALL
NCT03559413Phase 2Completed
- Sponsor
- University Children's Hospital Tübingen
- Start
- Jun 2016
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute lymphoblastic leukemia (ALL), sponsored by University Children's Hospital Tübingen. Primary endpoint: Success of treatment (T-cell response and safety) at 120 days. Started Jun 2016; status: completed.
02
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03559413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559413.